HPR81 Evaluation of the Hungarian Generic Program Between 2010 and 2021

Abstract

In Hungary, there is no regular price revision for originator products, so it is reasonable to assume that the distributor of the originator product would not in principle reduce the price. In 2010, the rules of the active substance or therapy based reference pricing were significantly tightened, allowing for a reduction in drug budget expenditure. In our research, we investigate how much the reference price reimbursement, which has been in place since 2011, has been able to reduce pharmaceutical expenditure and how much it has saved.